oral semaglutide novo Approved to Reduce the Risk of Cardiovascular Events Novo Nordisk stock rises as

Neuroprotective Effects Emerging evidence suggests that GLP-1 may play a role in protecting neurons, improving cognition, and reducing neuroinflammation

Moreover, side effect profiles vary between the two

About 31.2% of participants on 7.2 mg achieved at least 25% weight loss a number that previously belonged almost exclusively to triple-agonist territory (retatrutide hit 28.7% in TRIUMPH-4 on the 12 mg dose)

Also, the research identified opposite directions of intracellular metabolic fluxes between the MCFA intermediates C6:0 and C8:0, further highlighting the unique characteristics of MCFA metabolism

Diabetic Retinopathy: Patients with diabetic retinopathy should be monitored